Multiply Labs, Inc.

Based in San Francisco, US, and founded in 2016, Multiply Labs, Inc. specializes in developing robotic systems for the industrial-scale manufacturing of gene-modified cell therapies. The company was co-founded by Fred (Federico) Parietti (CEO), Alice Melocchi (CSO), Joe Wilson (COO), Tiffany Kuo, and Zack Bright. In October 2026, Multiply Labs, Inc.

raised USD 75 million in series B funding led by NantVentures, with participation from AstraZeneca, Teradyne Inc. , Lingotto Investment Management, Strange Ventures, Lux Capital, Founders Fund, Casdin Capital, Fifty Years, and Ora Global. As part of the transaction, Ileana Pirozzi of Lingotto Investment Management will join the company's board. Multiply Labs develops advanced robotic systems designed for the manufacturing of precision medicines, particularly gene-modified cell therapies, at an industrial scale.

Their technology streamlines production processes in the life sciences sector, offering a modular platform that enables high-throughput capabilities through tailored robotic modules. The company caters to a diverse clientele in biotechnology and pharmaceuticals, focusing on markets in North America, Europe, and Asia. Multiply Labs generates revenue primarily through partnerships and subscription models with biotechnology and pharmaceutical firms. Their transactions revolve around the sale or leasing of robotic manufacturing systems supported by service agreements, including digital process control and maintenance.

Their core offerings, such as Digital Quality Control systems and cell therapy capsules, are integrated into clients' production lines, ensuring compliance with Good Manufacturing Practices. The company plans to use the October 2026 funding to increase manufacturing capacity, accelerate product development, expand its engineering, regulatory, and commercial teams, and support the transition from clinical-stage deployments to commercial-scale production.